AssetMark Inc’s Revolution Medicines RVMD Stock Holding History

AssetMark Inc’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.29M	Buy	11,176 +4,587	+70%	+$909K	﹤0.01%	920
2026 Q2	$1.23M	Buy	6,589 +6,404	+3,462%	+$935K	﹤0.01%	1051
2026 Q1	$18K	Buy	185 +53	+40%	+$5.35K	﹤0.01%	2092
2025 Q4	$10.5K	Buy	132 +39	+42%	+$2.56K	﹤0.01%	2200
2025 Q3	$4.34K	Sell	93 -5	-5%	-$196	﹤0.01%	2393
2025 Q2	$3.6K	Buy	98 +86	+717%	+$3.3K	﹤0.01%	2241
2025 Q1	$424	Hold	12	–	–	﹤0.01%	2448
2024 Q4	$525	Buy	12 +10	+500%	+$505	﹤0.01%	2365
2024 Q3	$91	Buy	+2	New	+$87	﹤0.01%	2206
2024 Q1	–	Sell	-6	Closed	-$172	–	2089
2023 Q4	$172	Buy	+6	New	+$144	﹤0.01%	1783

Other funds holding RVMD

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Mass General Brigham Somerville, Massachusetts $456M AUM 27.51% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

AssetMark Inc's RVMD Position: Q3 2026 in Review

AssetMark Inc increased its Revolution Medicines (RVMD) stake by 70% in Q3 2026, buying an estimated $909K and bringing the position to 11,176 shares worth $2.29M. The position accounts for ﹤0.01% of the portfolio, ranked #920.

AssetMark Inc first reported a position in RVMD in Q4 2023 and has held it in 10 quarters since. 283 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

AssetMark Inc held 11,176 shares of Revolution Medicines worth $2.29M as of Q3 2026.
AssetMark Inc bought 4,587 Revolution Medicines shares in Q3 2026, an estimated $909K.
Revolution Medicines made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #920 holding.
AssetMark Inc first reported a position in Revolution Medicines in Q4 2023 and has held it in 10 quarters since.
283 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.